Related Experiment Video

Updated: Oct 12, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Genetic and Enzymatic Characteristics of CYP2A13 in Relation to Lung Damage

Radim Vrzal1

  • 1Department of Cell Biology and Genetics, Faculty of Science, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic.

International Journal of Molecular Sciences
|November 27, 2021
PubMed

Insights

Cytochrome P450 2A13 (CYP2A13) is crucial for lung health, metabolizing drugs and influencing toxicant-induced lung injury and cancer. This review covers its substrates, inhibitors, genetic variations, and regulation.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Toxicology

Background:

  • Cytochrome P450 2A13 (CYP2A13) is an enzyme with significant extrahepatic expression, particularly in the lungs.
  • Despite its role in pulmonary health and disease, CYP2A13 has received less attention compared to the liver-focused CYP2A6.
  • CYP2A13 is implicated in toxicant-induced pulmonary lesions and lung cancer development.

Purpose of the Study:

  • To provide a mini-review summarizing current knowledge on Cytochrome P450 2A13.
  • To focus on substrates, inhibitors, genetic polymorphisms, and transcriptional regulation of CYP2A13.
  • To consolidate information available up to September 2021.

Main Methods:

  • Literature review of scientific publications up to September 2021.
  • Synthesis of existing data on CYP2A13.
  • Focus on biochemical and genetic aspects of the enzyme.

Main Results:

  • Detailed information on known substrates and inhibitors of CYP2A13.
  • Overview of significant genetic polymorphisms affecting CYP2A13 activity.
  • Summary of factors influencing CYP2A13 transcriptional regulation.

Conclusions:

  • CYP2A13 plays a critical role in lung toxicology and carcinogenicity.
  • Understanding CYP2A13's substrates, inhibitors, and genetic variations is vital for lung disease research.
  • Further research into CYP2A13 regulation and function is warranted.
Keywords:
FOXA2NNKaflatoxinlung cancerpolymorphismregulationskatole

More Related Videos

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

14.0K
Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

11.3K

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
19
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
338
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
17
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
17
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
293